RESUMO
Cyclosporine A (CsA) is an immunosuppressive drug used in transplantation and treatment of autoimmune diseases. Experimental studies revealed impairments in liver function and morphology among cyclosporine-treated animals. The aim of the study was to evaluate hepatoprotective activity of peroxisome-proliferator-activated receptors γ (PPARγ) ligands: rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 (PGDJ2) on CsA-induced hepatotoxicity in experimental animals. CsA was administered subcutaneously at a dose of 15 mg/kg/day for 28 days. Both PPARγ agonists were given for 28 days 0.5 hour before the administration of CsA. Rosiglitazone was administered orally at a dose of 8 mg/kg/day and PGDJ2 was given intraperitoneally at a dose of 30 µg/kg/day. CsA induced liver injury was evidenced by increased serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin. Concentrations of glutathione (GSH) and glutathione disulfide (GSSG), lipid peroxidation products, nicotinamide adenine dinucleotide+/nicotinamide adenine dinucleotide hydrogen (NAD+/NADH), nicotinamide adenine dinucleotide phosphate+/nicotinamide adenine dinucleotide phosphate hydrogen (NADP+/NADPH) and adenosine diphosphate/adenosine triphosphate (ADP/ATP) ratios and caspase 3 activity that were measured in the liver tissue showed, that CsA induced oxidative stress, evoked an imbalanced redox state and apoptosis in the liver. Microscope examination showed sinusoidal dilatation, mononuclear cell infiltration, necrosis of hepatocytes, intracellular vacuolar degeneration and microvesicular steatosis and apoptopic cells. The biochemical and morphological changes induced by CsA were limited by administration of both PPARγ agonist - rosiglitazone and PGDJ2. Our biochemical and liver histopathological examination indicate that both PPARγ agonists may play an important role in protecting against CsA-induced hepatotoxicity.